A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane

PHASE3Active, not recruitingINTERVENTIONAL

Enrollment

381

Participants

Timeline

Start Date

August 4, 2022

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions

HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane

Interventions

DRUG

SHR-A1811

SHR-A1811 4.8mg/kg

DRUG

Pyrotinib in combination with Capecitabine.

DRUG

SHR-A1811

SHR-A1811 6.4mg/kg

Trial Locations (1)

Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou

All Listed Sponsors

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY